Author:
Grimaldi Franco,Vescini Fabio,Kara Elda
Publisher
Springer International Publishing
Reference105 articles.
1. Basuroy R, Bouvier C, Ramage JK, et al. Delays and routes to diagnosis of neuroendocrine tumors. BMC Cancer. 2018;18:1122.
2. Veltroni A, Cosaro E, Spada F, et al. Clinico-pathological features, treatments and survival of malignant insulinomas: a multicenter study. Eur J Endocrinol. 2020;182(4):439–46.
3. Tapia Rico G, Li M, Pavlakis N, et al. Prevention and management of carcinoid crisis in patients with high-risk neuroendocrine tumors undergoing peptide receptor radionuclide therapy (PRRT): literature review and case series from two Australian tertiary medical institutions. Cancer Treat Rev. 2018;66:1–6.
4. Beaumont JL, Cella D, Phan AT, et al. Comparison of health-related quality of life in patients with neuroendocrine tumors with quality of life in the general US population. Pancreas. 2012;41(3):461–6.
5. Citterio D, Pusceddu S, Facciorusso A, et al. Primary tumor resection may improve survival in functional well-differentiated neuroendocrine tumors metastatic to the liver. J Cancer Surg. 2017;43:380–7.